{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:18:11Z","timestamp":1785417491373,"version":"3.56.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Germinal predisposition to malignancy is found in approximately 10% of oncological pediatric patients. As awareness of cancer risk factors associated with germline mutations increases, and with advancements in molecular techniques, more carefully selected patients are being tested. This approach enables the identification of new variants\u2014both those that are clearly linked to tumorigenesis and candidates, which biological role needs to be functionally verified. Pathogenic variants within cancer-predisposing genes not only increase nearly eightfold the risk of secondary cancers but also may be associated with excessive toxicity of antineoplastic treatment. We present the case of a girl who developed classical Hodgkin lymphoma at the age of 8 years and secondary Ewing sarcoma at the age of 16 years. Her father was diagnosed with classical Hodgkin lymphoma at the age of 27 years. Genetic testing revealed the carriership of a germline heterozygous variant in the <jats:italic>PALB2<\/jats:italic> gene (NM_024675.4:c.110G&amp;gt;A, p.Arg37His) in both the patient and her father. Since the patient was exposed to chemotherapy due to lymphoma prior to the development of secondary malignancy and the variant is classified as an aberration of unknown significance, the causative role of the <jats:italic>PALB2<\/jats:italic> variant remains uncertain. Nevertheless, the presented case may indicate the possible interplay between inherited genetic predisposition and the exposure to cytostatic drugs, which both are involved in promoting secondary cancers in pediatric patients.<\/jats:p>","DOI":"10.3389\/fonc.2025.1514697","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:53:20Z","timestamp":1739861600000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Hodgkin lymphoma and Ewing sarcoma in pediatric patient carrying germline PALB2 variant: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Jakub","family":"Czarny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wzi\u0105tek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pastorczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Szmyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borys","family":"Przybyszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Raciborska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Jo\u0144czyk-Potoczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Derwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline mutations in predisposition genes in pediatric cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12981","article-title":"Realising the promise of cancer predisposition genes","volume":"505","author":"Rahman","year":"2014","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2016.01.008","article-title":"Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool","volume":"59","author":"Jongmans","year":"2016","journal-title":"Eur J Med Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12874-021-01428-1","article-title":"Predictors for participation in DNA self-sampling of childhood cancer survivors in Switzerland","volume":"21","author":"Waespe","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8589","article-title":"Genetic risk for subsequent neoplasms among long-term survivors of childhood cancer","volume":"36","author":"Wang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"pkab007","DOI":"10.1093\/jncics\/pkab007","article-title":"Frequency of pathogenic germline variants in cancer-susceptibility genes in the childhood cancer survivor study","volume":"5","author":"Kim","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2020.11.042","article-title":"Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study","volume":"145","author":"Waespe","year":"2021","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-021-00254-0","article-title":"Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel","volume":"20","author":"Byrjalsen","year":"2021","journal-title":"Familial Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.46","article-title":"Compromised BRCA1-PALB2 interaction is associated with breast cancer risk","volume":"36","author":"Foo","year":"2017","journal-title":"Oncogene"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(20)30275-3","article-title":"Predisposition to cancer in children and adolescents","volume":"5","author":"Kratz","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2022.04.007","article-title":"Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes","volume":"109","author":"Gillani","year":"2022","journal-title":"Am J Hum Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.206","article-title":"Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma","volume":"19","author":"Brohl","year":"2017","journal-title":"Genet Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30147-4","article-title":"Monogenic and polygenic determinants of sarcoma risk: an international genetic study","volume":"17","author":"Ballinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0094","article-title":"The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets","volume":"11","author":"van Tilburg","year":"2021","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1631","article-title":"Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing","volume":"11","author":"Newman","year":"2021","journal-title":"Cancer Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140208","article-title":"Exploring the roles of PALB2 at the crossroads of DNA repair and cancer","volume":"460","author":"Pauty","year":"2014","journal-title":"Biochem J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41467-020-14563-y","article-title":"PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1","volume":"11","author":"Belotserkovskaya","year":"2020","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2009.02.018","article-title":"PALB2 links BRCA1 and BRCA2 in the DNA-damage response","volume":"19","author":"Zhang","year":"2009","journal-title":"Curr Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms18091886","article-title":"The role of PALB2 in the DNA damage response and cancer predisposition","volume":"18","author":"Nepomuceno","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22022","article-title":"Rare germline mutations in PALB2 and breast cancer risk: a population-based study","volume":"33","author":"Tischkowitz","year":"2012","journal-title":"Hum Mutat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3390\/cancers13164195","article-title":"Germline PALB2 mutation in high-risk chinese breast and\/or ovarian cancer patients","volume":"13","author":"Kwong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/59147","article-title":"The risk of breast cancer due to PALB2 gene mutations","volume":"26","author":"Weso\u0142a","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10689-011-9426\u20131","article-title":"PALB2 mutations in familial breast and pancreatic cancer","volume":"10","author":"Hofstatter","year":"2011","journal-title":"Fam Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2018.11.010","article-title":"A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer","volume":"43","author":"Vel\u00e1zquez","year":"2019","journal-title":"Breast"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1405784","article-title":"PALB2 mutations and breast-cancer risk","volume":"371","author":"Evans","year":"2014","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2010.01425.x","article-title":"PALB2 mutations in European familial pancreatic cancer families","volume":"78","author":"Slater","year":"2010","journal-title":"Clin Genet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01410-0","article-title":"PALB2 mutations and prostate cancer risk and survival","volume":"125","author":"Woko\u0142orczyk","year":"2021","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5194","article-title":"Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer","volume":"3","author":"Pearlman","year":"2017","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41698-022-00291-7","article-title":"PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer","volume":"6","author":"Dillon","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.10.002","article-title":"PALB2 variants: protein domains and cancer susceptibility","volume":"7","author":"Nepomuceno","year":"2021","journal-title":"Trends Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-019-0115-9","article-title":"Homologous recombination DNA repair defects in PALB2-associated breast cancers","volume":"5","author":"Li","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0582-4","article-title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","volume":"25","author":"Staaf","year":"2019","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers14040897","article-title":"Precision medicine for BRCA\/PALB2-mutated pancreatic cancer and emerging strategies to improve therapeutic responses to PARP inhibition","volume":"14","author":"Principe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7067","article-title":"Germline PALB2 variants and PARP inhibitors in endometrial cancer","volume":"19","author":"Cilento","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0682-z","article-title":"Functional characterization of 84 PALB2 variants of uncertain significance","volume":"22","author":"Wiltshire","year":"2020","journal-title":"Genet Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109269","article-title":"Prevalence and clinical implications of germline pathogenic variants in cancer predisposing genes in young patients across sarcoma subtypes","volume":"61","author":"de Carvalho N de","year":"2024","journal-title":"J Med Genet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e67538","DOI":"10.1371\/journal.pone.0067538","article-title":"Analysis of PALB2 gene in BRCA1\/BRCA2 negative Spanish hereditary breast\/ovarian cancer families with pancreatic cancer cases","volume":"8","author":"Blanco","year":"2013","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1055\/a-1404-3243","article-title":"Heterozygous PALB2 mutation in a boy with acute lymphoblastic leukemia and subsequent metastatic ewing sarcoma","volume":"233","author":"Mehaffey","year":"2021","journal-title":"Klin Padiatr"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1038\/s41467-019-13194-2","article-title":"Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2","volume":"10","author":"Boonen","year":"2019","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz780","article-title":"A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor","volume":"47","author":"Rodrigue","year":"2019","journal-title":"Nucleic Acids Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1514697\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:53:22Z","timestamp":1739861602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1514697\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":47,"alternative-id":["10.3389\/fonc.2025.1514697"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1514697","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"1514697"}}